The analgesia produced by combinations of low-dose naloxone with pentazocine or morphine was studied in 105 patients with moderately severe postoperative pain after standardized surgery for removal of impacted third molars. Pain intensity was quantified using a visual-analogue scale. To eliminate the release of endogenous opioids produced by the placebo component of open drug administration, all injections were made by a preprogrammed infusion pump. The analgesia produced by pentazocine, an agonistantagonist opiate-analgesic acting predominantly at the kappa opiate receptor, was potentiated by low-dose naloxone, whereas the analgesia produced by morphine, a muagonist, was attenuated by low-dose naloxone. To evaluate whether similar potentiation would be present in an animal model, and specifically, in the absence of diazepam, which patients receive, we performed an analogous experiment in rats in which nociceptive threshold was determined using the Randall-Selitto paw-withdrawal test. The results were completely analogous to the clinical results: pentazocine analgesia was potentiated by lowdose naloxone, whereas morphine analgesia was attenuated by low-dose naloxone. These data demonstrate a novel interaction between opiates, and suggest a rationale for opiate combinations to produce potent analgesia with fewer autonomic side effects and less abuse potential than presently available analgesics. 
Introduction
The opiate-antagonist naloxone, administered at high doses, increases pain when administered in the presence of opiateanalgesics or under conditions when endorphins are probably released (1) (2) (3) (4) . When administered at low doses, however, naloxone produces analgesia in humans (3) (4) (5) and raises nociceptive thresholds in animals (6) (7) (8) . Although of low potency, naloxone has valuable features that would make it an "ideal" analgesic. It does not produce the common side effects that are present with other opiate analgesics (mental obtundation, cardiovascular and respiratory depression, constipation, and dysphoria) (9) , and it has low abuse and addiction potential (9) .
Since it is stereospecific, the increase in pain produced by naloxone is thought to be due to its antagonism of endogenous opioid-peptide interactions with opiate receptors (10) . The mechanism underlying low-dose naloxone analgesia, however, is unknown. That low-dose naloxone produces analgesia by an unusual mechanism is suggested by the fact that the biphasic dose-dependent relationship of its effect on pain does not resemble the dose-dependent relationship of any other opiate analgesic; i.e., no other opiate produces analgesia only at low doses.
Opiate agonists produce analgesia by acting at one or more receptors (i.e., mu, kappa, and delta) (1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . A single opiate administered simultaneously at different sites in the central nervous system can synergize to produce greater analgesia ( 14, 15) . Since naloxone is believed to interact with opiate receptors (i.e., it produces hyperalgesia at high doses) we hypothesized that low-dose naloxone might be able to potentiate the analgesia of other opiates. We report that the analgesia produced by pentazocine, an agonist-antagonist opiate-analgesic acting predominantly at the kappa opiate receptor (16, 17) , is potentiated by low-dose naloxone, whereas the analgesia produced by morphine, an agonist opiate-analgesic at the mu opiate receptor, is attenuated by low-dose naloxone. Furthermore, we report that this interaction exists in a standard animal model.
Methods
105 patients underwent standardized surgery for the removal of impacted third molars after premedication with intravenous diazepam. The surgical procedure and the visual-analogue scale used for measuring pain have been described in detail elsewhere (18) . During (15) . The time of substance administration was varied randomly between 1 h and 20 min and 2 h (average, 1 h and 40 min) after the onset of anesthesia and was the same for all groups of patients.
Since baseline pain levels ( Fig. 1 ) did not differ significantly among the seven experimental groups (F[6,98] = 0.6, NS), the magnitude of the analgesic effect ofeach intervention was defined as the change from the pain intensity before drug administration to 50 min (peak analgesia) and to 3 h and 10 min (end of experiments after administration of a drug or combination oftwo drugs). Magnitudes ofanalgesic effect for the various drug treatments were compared using Neuman-Keuls' post hoc comparison (19) after analysis of variance, which demonstrated significant difference between the groups both at 50 min (F [ 1, 6] -10.8, P < 0.0001) and at 3 h and O min (F(1,6) = 4.0, P < 0.01).
Mechanical nociceptive thresholds were measured in 250-300-g male Sprague-Dawley rats (Bantin & Kingman, Fremont, CA) using a Basile analgesymeter (Stoelting Co., Chicago, IL), which generates a linearly increasing mechanical force that is applied by a conical piece of plastic with a dome-shaped tip, on the dorsal surface of the rat's hindpaw (20, 21) . The nociceptive threshold is defined as the force in grams at which the rat withdraws its paw. The rats were trained in this procedure for 2 h daily in the week before experimentation. On the day of the experiment, the rats were exposed to the test stimulus at 5-min intervals for 2 h before the measurement of baseline thresholds. The baseline threshold was defined as the mean of the last six determinations. Rats were then injected with graded subcutaneous doses of opioid, or opioid combinations. Vehicle injection has been shown to have no effect (20, 21 Compared with the control group, the mean pain intensity measured at 3 h and 10 min after injection of single analgesic agents was not significantly decreased (Fig. 1 B) . In addition, the analgesia produced by the combination of low-dose naloxone and 8 mg morphine did not differ significantly from the analgesia produced by the same dose of morphine. The combination of low-dose naloxone and pentazocine, however, continued to produce significant analgesia when compared with either agent alone (both P < 0.01). That is, by 3 h and 10 min after injection only the group of patients receiving low-dose naloxone plus pentazocine still reported significant analgesia.
Animal studies. To address the possibility, raised during the review process, that an interaction with diazepam was responsible for the results, we performed an analogous experiment in rats in which diazepam could be omitted.
Naloxone produced a biphasic dose-dependent analgesia. At low doses (50 ng/kg, 500 ng/kg, and 5 gg/kg) naloxone produced analgesia; this disappeared when naloxone doses were increased to 50 ,gg/kg and 500 ug/kg (Fig. 2 A) . Pentazocine and morphine both produced dose-dependent analgesia (Fig. 2, B and C) .
When administered in combinations, 50 ng naloxone, which by itself produced a 9.2±3.5% (n = 9) increase in nociceptive threshold, significantly reduced the analgesia produced by 1 mg morphine (from 34.7±12.6% (n = I 1) to 13.8±2.9% (n = 19; P < 0.05) (Fig. 3) . On the other hand, the same dose of naloxone, when given in combination with a 5-Ag dose of pentazocine, which by itself produces an increase in nociceptive threshold of 24.8±3.0% (n = 23), produces a resultant increase in threshold of 53.1±7.9% (n = 10). This is significantly greater than either agent alone (P < 0.01 and P < 0.01, respectively) and even greater than the effect of a 10-fold- higher dose of pentazocine (50 jig, 30 .9±4.1, n = 23, P < 0.05) or naloxone (500 ng, 15.9±3.5%, n = 22, P < 0.01).
Discussion
In this study, we have evaluated the analgesic effect resulting from the administration of a low dose of the opiate-antagonist naloxone along with two opiate agonists, morphine (a mu type) and pentazocine (a kappa type), to patients with postoperative pain and to animals during nociceptive threshold testing. Since naloxone is a potent antagonist of the mu-type opiate receptor, at which morphine acts to produce analgesia, the observed antagonism of morphine analgesia by naloxone was expected. However, pentazocine and low-dose naloxone unpredictably produced a more potent and prolonged analgesia than either drug alone. This analgesia was, in fact, significantly greater than that produced by high-dose morphine, even though kappa-agonists such as pentazocine are less potent than mu-agonists such as morphine, and produce analgesia of shorter duration (23, 24) . Since the half-life of naloxone in humans is only 60 min (25) , the prolonged (up to 3 h) analgesia produced by low-dose naloxone plus pentazocine in humans suggests that significantly lower doses of naloxone than those employed in this study may be sufficient to potentiate pentazocine analgesia. Although potent opiate synergism has been described previously, e.g., when morphine has been simultaneously injected into both the intrathecal and intracerebroventricular spaces (14, 15) , the synergism that has been reported for combinations of opiate agonists and antagonists (26) (29) and for mu-and delta-mediated analgesia in vivo (30) (31) (32) .
In summary, this study has demonstrated a marked analgesia, more potent than that of high-dose morphine, produced by the combination of low-dose naloxone and pentazocine.
This finding is of considerable experimental as well as clinical importance since it demonstrates a novel, potent interaction between different opiates as well as a rationale for new opiate combinations that produce profound analgesia.
